Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer

Abstract

A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.

1 . An antibody or fragment thereof that binds specifically to a 282P1G3 protein. 
     
     
         2 . The antibody of  claim 1 , wherein the 282P1G3 protein has a sequence selected from the group consisting of SEQ ID NO: 5, 9, 11, 13, 15, 17, 19, and 208. 
     
     
         3 . An isolated monoclonal antibody or fragment thereof comprising an antigen binding site that binds specifically to a 282P1G3 protein. 
     
     
         4 . The antibody or fragment of  claim 3 , wherein the 282P1G3 protein has a sequence selected from the group consisting of SEQ ID NO: 5, 9, 11, 13, 15, 17, 19, and 208. 
     
     
         5 . The antibody or fragment of  claim 3 , wherein the monoclonal antibody is a humanized antibody. 
     
     
         6 . The antibody or fragment of  claim 3 , wherein the fragment is an Fab, F(ab′) 2 , Fv or Sfv fragment. 
     
     
         7 . The antibody or fragment of  claim 3 , wherein the antibody is a fully human antibody. 
     
     
         8 . The antibody or fragment of  claim 3 , wherein the antigen binding site is a murine antigen binding domain. 
     
     
         9 . The antibody or fragment of  claim 3 , which is recombinantly produced. 
     
     
         10 . The antibody or fragment of  claim 9 , wherein the recombinant protein comprises the antigen binding region. 
     
     
         11 . The antibody or fragment of  claim 1 , wherein the antibody is coupled to a detectable marker, a toxin, a therapeutic agent, or a chemotherapeutic agent. 
     
     
         12 . The antibody or fragment of  claim 11 , wherein the detectable marker is a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound. 
     
     
         13 . The antibody or fragment of  claim 12 , wherein the radioisotope comprises  212 Bi,  131 I,  131 In,  90 Y,  186 Re,  211 At,  125 I,  188 Re,  153 Sm,  213 Bi,  32 P, or Lu. 
     
     
         14 . The antibody or fragment of  claim 11 , wherein the toxin comprises ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin,  Pseudomonas  exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatin, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolostatin, cc1065, or a cisplatin. 
     
     
         15 . A transgenic animal that produces the monoclonal antibody of  claim 3 . 
     
     
         16 . A hybridoma that produces the monoclonal antibody of  claim 3 . 
     
     
         17 . A vector comprising a polynucleotide encoding an antibody of  claim 3 . 
     
     
         18 . The vector of  claim 17  that is a single-chain comprising variable domains of heavy and light chains. 
     
     
         19 . A pharmaceutical composition that comprises the antibody or fragment of  claim 1  in a human unit dose form.